SCHEMBL3340576

SCHEMBL3340576

FC(F)(F)c1ccc2nc(Cl)cn2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.54
NPC1 O15118 5/20 0.54
RAB9A P51151 4/20 0.54
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 3/20 0.54
NFKB1 P19838 3/20 0.54
NFKB2 Q00653 3/20 0.54
RELA Q04206 3/20 0.54
HPGD P15428 2/20 0.54
POLB P06746 1/20 0.54
GFER P55789 1/20 0.54
RCE1 Q9Y256 1/20 0.54
MAPT P10636 2/20 0.42
TRPA1 O75762 1/20 0.41
USP7 Q93009 1/20 0.40
DYRK1A Q13627 1/20 0.39
DYRK2 Q92630 1/20 0.39
MCHR1 Q99705 6/20 0.38
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8814197 0.78 MCHR1 (0.57) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL16648467 0.78 KDM4E (0.54) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL3486088 0.78 PIK3CG (0.55) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL19086907 0.78 KDM4E (0.54) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL12778283 0.78 KDM4E (0.54) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL8174380 0.77 KDM4E (0.50) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL720360 0.77 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL1691401 0.77 NPC1 (0.74) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL13791874 0.75 KDM4E (0.51) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL755503 0.75 APP (0.46) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220217979-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-07-14 US disclosed
EP-3928607-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-29 EP disclosed
US-20210380610-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-09 US disclosed
EP-3918896-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROL COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-08 EP disclosed
WO-2021141106-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION INCLUDING SAME 住友化学株式会社 2021-07-15 WO disclosed
WO-2020158889-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROL COMPOSITION CONTAINING SAME 住友化学株式会社 2020-08-06 WO disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380610-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME C5, COX6C, C3AR1 SMN1; SMN2 2000/4885NPC1 1947/4885RAB9A 959/4885
US-20220217979-A1 HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME C5, COX6C, C1S SMN1; SMN2 2054/4885NPC1 2265/4885RAB9A 665/4885
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 SMN1; SMN2 2046/4885NPC1 241/4885RAB9A 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.